17 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp07517 | LL-37 Analogue 2 | LKRIVQRIKDFLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 33.7 µg/mL |
| dbacp07518 | LL-37 Analogue 3 | AKRIVQRIKDFLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 29.8 µg/mL |
| dbacp07519 | LL-37 Analogue 4 | FΚRIVQRILDFLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 3.9 µg/mL |
| dbacp07520 | LL-37 Analogue 5 | FKSARIVQRILDFLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 10.7 µg/mL |
| dbacp07521 | LL-37 Analogue 6 | FKRIVQRIRDFLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 56 µg/mL |
| dbacp07522 | LL-37 Analogue 7 | FKRIVQRIRDFLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 12.5 µg/mL |
| dbacp07523 | LL-37 Analogue 8 | FKRIVQKIKDFLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 145 µg/mL |
| dbacp07524 | LL-37 Analogue 9 | FKRIVQLIKDFLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 18.9 µg/mL |
| dbacp07525 | LL-37 Analogue 10 | FKRIVQLIKDFLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 13.9 µg/mL |
| dbacp07526 | LL-37 Analogue 11 | FKRIVQRIKDLLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 75 µg/mL |
| dbacp07527 | LL-37 Analogue 12 | FKRIVQRIKDLLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 45.5 µg/mL |
| dbacp07528 | LL-37 Analogue 13 | FKRIVQIIKKFLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 20.0 µg/mL |
| dbacp07529 | LL-37 Analogue 14 | FKRIVQIIKKFLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 12.9 µg/mL |
| dbacp07530 | LL-37 Analogue 15 | FKRIVQLLKKLLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 12.8 µg/mL |
| dbacp07531 | LL-37 Analogue 16 | FKRIVQLLKKLLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 9.8 µg/mL |
| dbacp07532 | LL-37 Analogue 17 | FKRILQRIKDFLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 19.2 µg/mL |
| dbacp07533 | LL-37 Analogue 18 | FKRILQRIKDFLR | Synthetic Analog of LL-37 | Helical peptides disrupt cancer membranes | MTT assay | A-549 | Lung Cancer | IC50 = 29.2 µg/mL |